查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413074

重症肌無力治療藥物市場：按類型、最終用戶分類 - 全球預測 2024-2030

Myasthenia Gravis Treatment Market by Type (Medication, Surgery), End-User (Clinics, Hospitals) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年重症肌無力治療市場規模為19.3億美元，預計2024年將達20億美元，2030年將達到27.6億美元，複合年成長率為5.21%。

重症肌無力治療藥物的全球市場

主要市場統計
基準年[2023] 19.3億美元
預測年份 [2024] 20億美元
預測年份 [2030] 27.6億美元
複合年成長率（%） 5.21%
重症肌無力治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估重症肌無力治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對重症肌無力治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-重症肌無力治療藥物市場的市場規模和預測是多少？

2-重症肌無力治療藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-重症肌無力治療藥物市場的技術趨勢和法律規範是什麼？

4-重症肌無力治療藥物市場主要供應商的市場佔有率是多少？

5-進入重症肌無力藥物市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的老年人口正在增加
      • 重症肌無力導致眼睛腫脹的病例增加
      • 更多治療臨床試驗
    • 抑制因素
      • 治療費用高昂
    • 機會
      • 改善醫療基礎設施
      • 藥物開發管線研究數量快速增加
    • 任務
      • 與藥物相關的副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章重症肌無力治療藥物市場：依類型

  • 藥品
  • 外科手術

第7章重症肌無力治療藥物市場：依最終使用者分類

  • 診所
  • 醫院

第8章北美和南美重症肌無力治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區重症肌無力治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲重症肌無力治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • Alexion Pharmaceutical Inc.
    • Argenx
    • Avadel Pharmaceuticals, PLC
    • Bausch Health Companies Inc.
    • Catalyst Pharmaceuticals Inc.
    • CSL Behring AG
    • F.Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Mitsubishi Tanabe Pharma Corporation
    • Pfizer, Inc.
    • Sandoz Inc. by Novartis AG
    • Sun Pharmaceuticals Industries
    • Taj Pharmaceuticals Ltd.
    • Takeda Pharmaceuticals Company Limited
    • Troikaa Pharmaceuticals Ltd.
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-0A609A26A9CC

[199 Pages Report] The Myasthenia Gravis Treatment Market size was estimated at USD 1.93 billion in 2023 and expected to reach USD 2.00 billion in 2024, at a CAGR 5.21% to reach USD 2.76 billion by 2030.

Global Myasthenia Gravis Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.93 billion
Estimated Year [2024] USD 2.00 billion
Forecast Year [2030] USD 2.76 billion
CAGR (%) 5.21%
Myasthenia Gravis Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Myasthenia Gravis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Myasthenia Gravis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Myasthenia Gravis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceutical Inc., Argenx, Avadel Pharmaceuticals, PLC, Bausch Health Companies Inc., Catalyst Pharmaceuticals Inc., CSL Behring AG, F.Hoffmann-La Roche AG, GlaxoSmithKline PLC, Mitsubishi Tanabe Pharma Corporation, Pfizer, Inc., Sandoz Inc. by Novartis AG, Sun Pharmaceuticals Industries, Taj Pharmaceuticals Ltd., Takeda Pharmaceuticals Company Limited, and Troikaa Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Myasthenia Gravis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Medication
    • Surgery
  • End-User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Myasthenia Gravis Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Myasthenia Gravis Treatment Market?

3. What are the technology trends and regulatory frameworks in the Myasthenia Gravis Treatment Market?

4. What is the market share of the leading vendors in the Myasthenia Gravis Treatment Market?

5. Which modes and strategic moves are suitable for entering the Myasthenia Gravis Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Myasthenia Gravis Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population across the globe
      • 5.1.1.2. Increasing cases of swollen eyes due to Myasthenia Gravis
      • 5.1.1.3. Rising clinical trials for treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving healthcare infrastructure
      • 5.1.3.2. Upsurge in the number of pipeline studies for drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Myasthenia Gravis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Surgery

7. Myasthenia Gravis Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals

8. Americas Myasthenia Gravis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Myasthenia Gravis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Myasthenia Gravis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Alexion Pharmaceutical Inc.
    • 12.1.3. Argenx
    • 12.1.4. Avadel Pharmaceuticals, PLC
    • 12.1.5. Bausch Health Companies Inc.
    • 12.1.6. Catalyst Pharmaceuticals Inc.
    • 12.1.7. CSL Behring AG
    • 12.1.8. F.Hoffmann-La Roche AG
    • 12.1.9. GlaxoSmithKline PLC
    • 12.1.10. Mitsubishi Tanabe Pharma Corporation
    • 12.1.11. Pfizer, Inc.
    • 12.1.12. Sandoz Inc. by Novartis AG
    • 12.1.13. Sun Pharmaceuticals Industries
    • 12.1.14. Taj Pharmaceuticals Ltd.
    • 12.1.15. Takeda Pharmaceuticals Company Limited
    • 12.1.16. Troikaa Pharmaceuticals Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MYASTHENIA GRAVIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 9. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 98. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 99. MYASTHENIA GRAVIS TREATMENT MARKET LICENSE & PRICING